AbstractA regimen of three injections per day involving the NovoPen (Novo Laboratories Ltd, Basingstoke, Hants, UK) was assessed in eight adolescent diabetics (median age l3.5 years). Six months after the institution of this regimen there was an improvement in metabolic control (assessed by HbA1cmeasurements) and patient acceptability (assessed by questionnaire). This improvement was maintained for a further six‐month perio